# GPT-Rosalind — OpenAI's first domain-specific frontier reasoning model, for life sciences

> OpenAI's first purpose-built domain model — frontier reasoning tuned on molecules, proteins, genes, and experimental workflows.

- Org: OpenAI
- Date: 2026-04-16
- Category: model, tool
- Source: https://openai.com/index/introducing-gpt-rosalind/
- Canonical page: https://ai-tldr.dev/releases/openai-gpt-rosalind/

## In short

OpenAI ships GPT-Rosalind, a frontier reasoning model purpose-built for life sciences — evidence synthesis, hypothesis generation, experimental planning. Research preview via ChatGPT, Codex, and API for trusted-access enterprise customers (Amgen, Moderna, Allen Institute, Thermo Fisher).

## What it is

GPT-Rosalind, announced April 16 and rolling out April 17 in research preview, is OpenAI's first purpose-built domain-specific frontier reasoning model, aimed squarely at life sciences and drug discovery. Named after Rosalind Franklin, it is available through ChatGPT, Codex, and the API to a 'trusted access' program of qualified enterprise customers in the US — launch partners include Amgen, Moderna, the Allen Institute, and Thermo Fisher.

## How it works

The model is tuned for reasoning over molecules, proteins, genes, pathways, and disease-relevant biology. It supports multi-step scientific workflows: literature review, evidence synthesis, genomics analysis, hypothesis generation, experimental planning, and interpretation of research data. In Codex's internal evaluations, GPT-Rosalind submissions ranked above the 95th percentile of human experts on prediction tasks and reached the 84th percentile on sequence generation. During the preview, the model does not consume existing credits or tokens.

## Why it matters

Domain-specific frontier models are a different product category from general-purpose GPT-5.x — narrower but deeper. If the Codex prediction numbers hold outside OpenAI's internal eval, Rosalind is the first public frontier model explicitly designed as a lab partner rather than a chatbot. Combined with the parallel Novo Nordisk partnership announced the same week, this is OpenAI signaling a serious enterprise push into pharma.

## Who it's for

Biotech and pharma research teams; computational biologists; drug-discovery infra leads.

## Try it

https://openai.com/index/introducing-gpt-rosalind/ (research preview; trusted-access program)

## Links

- [Announcement](https://openai.com/index/introducing-gpt-rosalind/)
- [Euronews](https://www.euronews.com/health/2026/04/17/what-to-know-about-openais-new-model-for-life-sciences-research-gpt-rosalind)
- [Pharmaphorum](https://pharmaphorum.com/news/openai-introduces-gpt-rosalind-its-drug-discovery-ai)
- [Axios](https://www.axios.com/2026/04/16/openai-models-life-sciences-drugs)